La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Hebei Changshan Biochemical Pharmaceutical Résultats passés
Passé contrôle des critères 0/6
Hebei Changshan Biochemical Pharmaceutical's earnings have been declining at an average annual rate of -66.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 1.6% per year.
Informations clés
-66.5%
Taux de croissance des bénéfices
-66.9%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 10.9% |
Taux de croissance des recettes | -1.6% |
Rendement des fonds propres | -75.4% |
Marge nette | -108.6% |
Prochaine mise à jour des résultats | 29 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now
Jul 25Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Apr 15Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up
Mar 01Ventilation des recettes et des dépenses
Comment Hebei Changshan Biochemical Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Mar 24 | 1,203 | -1,306 | 570 | 137 |
31 Dec 23 | 1,410 | -1,240 | 646 | 159 |
30 Sep 23 | 1,682 | -438 | 600 | 130 |
30 Jun 23 | 2,010 | -203 | 660 | 147 |
31 Mar 23 | 2,264 | -8 | 687 | 147 |
01 Jan 23 | 2,336 | 18 | 746 | 145 |
30 Sep 22 | 2,603 | 94 | 918 | 160 |
30 Jun 22 | 2,697 | 141 | 1,035 | 150 |
31 Mar 22 | 2,832 | 195 | 1,115 | 146 |
01 Jan 22 | 2,968 | 234 | 1,220 | 151 |
30 Sep 21 | 2,885 | 255 | 1,217 | 149 |
30 Jun 21 | 2,771 | 279 | 1,203 | 139 |
31 Mar 21 | 2,676 | 273 | 1,189 | 145 |
31 Dec 20 | 2,364 | 253 | 1,100 | 128 |
30 Sep 20 | 2,280 | 236 | 1,132 | 127 |
30 Jun 20 | 2,178 | 233 | 1,098 | 138 |
31 Mar 20 | 2,011 | 217 | 1,029 | 136 |
31 Dec 19 | 2,071 | 225 | 1,045 | 136 |
30 Sep 19 | 1,930 | 173 | 972 | 111 |
30 Jun 19 | 1,841 | 157 | 901 | 103 |
31 Mar 19 | 1,783 | 151 | 853 | 105 |
31 Dec 18 | 1,653 | 140 | 776 | 99 |
30 Sep 18 | 1,691 | 225 | 721 | 98 |
30 Jun 18 | 1,621 | 219 | 623 | 126 |
31 Mar 18 | 1,493 | 199 | 613 | 94 |
31 Dec 17 | 1,420 | 197 | 577 | 76 |
30 Sep 17 | 1,189 | 208 | 462 | 59 |
30 Jun 17 | 1,119 | 190 | 508 | 0 |
31 Mar 17 | 1,143 | 190 | 487 | 0 |
31 Dec 16 | 1,118 | 175 | 484 | 0 |
30 Sep 16 | 1,082 | 171 | 493 | 0 |
30 Jun 16 | 1,008 | 165 | 451 | 0 |
31 Mar 16 | 949 | 161 | 414 | 0 |
31 Dec 15 | 916 | 156 | 400 | 0 |
30 Sep 15 | 895 | 147 | 351 | 0 |
30 Jun 15 | 877 | 139 | 336 | 0 |
31 Mar 15 | 831 | 135 | 326 | 0 |
31 Dec 14 | 811 | 134 | 296 | 0 |
30 Sep 14 | 716 | 119 | 298 | 0 |
30 Jun 14 | 693 | 116 | 264 | 0 |
31 Mar 14 | 723 | 116 | 255 | 0 |
31 Dec 13 | 705 | 115 | 242 | 0 |
30 Sep 13 | 733 | 110 | 229 | 0 |
Des revenus de qualité: 300255 is currently unprofitable.
Augmentation de la marge bénéficiaire: 300255 is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 300255 is unprofitable, and losses have increased over the past 5 years at a rate of 66.5% per year.
Accélération de la croissance: Unable to compare 300255's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: 300255 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Rendement des fonds propres
ROE élevé: 300255 has a negative Return on Equity (-75.43%), as it is currently unprofitable.